Eric Horlick

Eric Horlick

Auto-generated profile, based on publicly available information

Eric Horlick

Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in JACC
Verified
Journal Article
Closed access
JRJosep Rodés-Cabau
Josep Rodés-Cabau
JWJohn G. Webb
John G. Webb
ACAnson Cheung
Anson Cheung
JYJian Ye
Jian Ye
EDEric Dumont
Eric Dumont
EHEric Horlick
Eric Horlick

27 April 2010 in Circulation
Verified
Journal Article
Closed access
JWJohn G. Webb
John G. Webb
DWDavid A. Wood
David A. Wood
JYJian Ye
Jian Ye
RGRonen Gurvitch
Ronen Gurvitch
JMJean-Bernard Masson
Jean-Bernard Masson
ACAnson Cheung
Anson Cheung
Background— The majority of prosthetic heart valves currently implanted are tissue valves that can be expected to degenerate with time and eventually fail. Repeat cardiac surgery to replace these valves is associated with significant morbidity and mortality. Transcatheter heart valve implantation within a failed bioprosthesis, a “valve-in-valve” procedure, may offer a less invasive alternative. Methods and Results— Valve-in-valve implantations were performed in 24 high-risk patients. Failed valves were aortic (n=10), mitral (n=7), pulmonary (n=6), or tricuspid (n=1) bioprostheses. Implantation was successful with immediate restoration of satisfactory valve function in all but 1 patient. No patient had more than mild regurgitation after implantation. No patients died during the procedure. Thirty-day mortality was 4.2%. Mortality was related primarily to learning-curve issues early in this high-risk experience. At baseline, 88% of patients were in New York Heart Association functional class III or IV; at the last follow-up, 88% of patients were in class I or II. At a median follow-up of 135 days (interquartile range, 46 to 254 days) and a maximum follow-up of 1045 days, 91.7% of patients remained alive with satisfactory valve function. Conclusions— Transcatheter valve-in-valve implantation is a reproducible option for the management of bioprosthetic valve failure. Aortic, pulmonary, mitral, and tricuspid tissue valves were amenable to this approach. This finding may have important implications with regard to valve replacement in high-risk patients.

1 November 2012 in JACC
Verified
Journal Article
Closed access
JRJosep Rodés-Cabau
Josep Rodés-Cabau
JWJohn G. Webb
John G. Webb
ACAnson Cheung
Anson Cheung
JYJian Ye
Jian Ye
EDEric Dumont
Eric Dumont
EHEric Horlick
Eric Horlick

1 March 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DWDavid A. Wood
David A. Wood
SLSandra B. Lauck
Sandra B. Lauck
JCJohn A. Cairns
John A. Cairns
KHKarin H. Humphries
Karin H. Humphries
RCRichard Cook
Richard Cook
JWJohn G. Webb
John G. Webb

1 July 2013 in JACC
Verified
Journal Article
Closed access
MUMarina Urena
Marina Urena
JRJosep Rodés-Cabau
Josep Rodés-Cabau
XFXavier Freixa
Xavier Freixa
JSJacqueline Saw
Jacqueline Saw
JWJohn G. Webb
John G. Webb
Reda IbrahimReda Ibrahim
Reda Ibrahim

22 February 2016 in European Heart Journal
Verified
Journal Article
Open access
PDF file
HMHeinrich P. Mattle
Heinrich P. Mattle
SEStefan Evers
Stefan Evers
DHDavid Hildick-Smith
David Hildick-Smith
WBWerner J. Becker
Werner J. Becker
HBHelmut Baumgartner
Helmut Baumgartner
BMBernhard Meier
Bernhard Meier
Migraine with aura and patent foramen ovale (PFO) are associated. The Percutaneous Closure of PFO in Migraine with Aura (PRIMA) trial is a multicentre, randomized trial to investigate the effect of percutaneous PFO closure in patients refractory to medical treatment. Migraine with aura patients and PFO who were unresponsive to preventive medications were randomized to PFO closure or medical treatment. Both groups were given acetylsalicylic acid 75–100 mg/day for 6 months and clopidogrel 75 mg/day for 3 months. The primary endpoint was reduction in monthly migraine days during months 9–12 after randomization compared with a 3-month baseline phase before randomization. The committee reviewing the headache diaries were blinded to treatment assignment. One hundred and seven patients were randomly allocated to treatment with an Amplatzer PFO Occluder ( N = 53) or control with medical management ( N = 54). The trial was terminated prematurely because of slow enrolment. Eighty-three patients (40 occluder, 43 control) completed 12-month follow-up. Mean migraine days at baseline were 8 (±4.7 SD) in the closure group and 8.3 (±2.4) in controls. The primary endpoint was negative with −2.9 days after PFO closure vs. −1.7 days in control group ( P = 0.17). Patent foramen ovale closure caused five adverse events without permanent sequelae. In patients with refractory migraine with aura and PFO, PFO closure did not reduce overall monthly migraine days.